查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717728

眼科药物传输系统市场：按药物类型、输送装置类型、产品类型、配方类型、输送方式、应用和最终用户 - 2025-2030 年全球预测

Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode Of Delivery, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

眼科药物输送系统市场预计到 2024 年将达到 155 亿美元，2025 年将达到 168.4 亿美元，到 2030 年将达到 257.9 亿美元，复合年增长率为 8.84%。

主要市场统计数据
基准年2024年 155亿美元
预计2025年 168.4亿美元
预测年份 2030 257.9亿美元
复合年增长率（%） 8.84%

过去几年来，眼科药物传输领域经历了蓬勃发展，推动力来自于不断改善患者治疗效果和改进输送机制。在精准和效率至关重要的时代，先进技术的出现正在重塑眼科疾病的处方和用药方式。这种转变不仅满足了日益增长的以病人为中心的照护需求，也弥合了新药理研究与临床应用之间的差距。微米和奈米级递送系统的创新正在推动标靶治疗、最大限度地减少全身副作用和扩大治疗效果的重大进步。研究人员和医疗保健专业人员越来越关注优化生物有效性度同时保持药物稳定性和功效的配方策略，这使得该领域既充满挑战又充满回报。诊断和影像技术的进步为医疗保健专业人员提供了比以往更多的工具来根据每位患者的需求量身定制治疗方案。各个学科的无缝整合为未来眼科护理更加便捷、侵入性更小、更有效地治疗各种疾病奠定了基础。

随着产业进入新的研究领域，科学、技术和临床实践的交叉领域正在建立新的基准。技术创新与监管之间的持续对话进一步加强了我们对实现更高安全和性能标准的承诺。这全面的概况为理解眼科药物传递的复杂性和潜力提供了基础。

重新定义药物传递的转折点

传统的眼科药物传递领域正在经历根本性的转变，从传统方法转向创造性领域，以提高效率和患者舒适度。新兴技术正在整合先进材料和智慧设计原理，以优化药物配方和改进输送机制。这种变革性转变的特征是跨学科研究和最尖端科技的融合，为曾经被认为不可能的应用铺平了道路。生物技术的快速发展促进了微加工技术的应用，使得能够设计精准的药物输送装置，以前所未有的精度瞄准眼睛中的患病组织。

这种新模式意味着重新定义治疗通讯协定和病患管理策略，而不仅仅是技术力。远端医疗和穿戴式装置等数位健康解决方案的整合使医生能够即时监测治疗结果并以惊人的精度调整剂量。技术创新、临床洞察力和监管灵活性的结合使得新的治疗方法成为可能，有可能改善安全性并提高患者的依从性。随着产业的发展，学术界、产业专家和医疗机构之间的密切合作对于有效地将这些突破性技术从实验室转化为临床环境并全面加快药物输送系统创新的步伐至关重要。

详细了解市场区隔策略

眼科给药市场被复杂地细分为几个部分，以便全面了解市场动态和成长驱动因素。基于药物类型的评估涉及从抗过敏和抗青光眼药物到抗感染疾病、抗发炎和抗 VEGF 分子等配方的详细分析。每个类别在解决特定的眼科挑战中发挥关键作用，有助于推动市场扩张。药物传递装置类别进一步扩大了其重点，探索了隐形眼镜药物输送系统、眼内植入、微针系统、眼内插入物、眼科喷雾剂和外用凝胶等技术。这种技术的多样性不仅展示了技术创新的程度，也凸显了减少侵入性和提高病患依从性的努力。

根据产品类型，该报告涵盖非处方药和处方药配方，后者进一步细分为控制释放和标准配方，透过精确的剂量技术提供客製化解决方案。此外，配方类型根据液体、半固态和固态剂型对市场进行分类。半固态剂型类别（包括乳膏、凝胶和软膏）和固态剂型部分（以胶囊和锭剂为重点）揭示了传统治疗方法如何发展以满足现代治疗要求。此外，在给药方法方面，它考虑了眼内、眶内、眼周、全身和局部方法，而按应用细分则涵盖了广泛的应用，从过敏治疗和干眼症到青光眼、眼部感染疾病、视网膜疾病和术后恢復。最后，最终用户分析重点关注医院、眼科诊所和研究机构等关键位置，每个位置都为整体成长故事带来了独特的见解。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 随着人口老化，对先进药物输送系统的需求不断增加
      • 人们对用于眼内缓释的生物分解性和生物相容性药物载体的兴趣日益浓厚
      • 政府的支持措施和监管部门的核准将推动新型眼科给药解决方案的采用
    • 限制因素
      • 供应链中断和产品召回的潜在风险
      • 眼科给药系统开发中的药物配方复杂性与稳定性问题
    • 机会
      • 建立伙伴关係，共同开发尖端的下一代治疗方法
      • 投资和资金激增推动眼科给药创新
    • 任务
      • 眼科给药的副作用与安全风险
  • 市场区隔分析
    • 药物类型：预防视神经损伤的青光眼药物需求增加
    • 输送装置的类型：具有长期控制药物释放功能的眼内植入的重要性日益增加
    • 产品类型：可用性和广泛的消费者信任导致人们越来越偏好非处方配方
    • 剂型：增加半固态剂型的使用，以增强药物吸收及治疗效果
    • 给药方法：由于其精确标靶化的能力，眼内输送系统的采用正在增加。
    • 应用：扩大眼科药物传递系统在进行进行性青光眼的应用
    • 最终使用者：眼科药物传输系统在眼科诊所提供专业眼科护理和治疗的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 眼科给药系统市场（依药物类型）

  • 抗过敏
  • 青光眼预防
  • 抗感染
  • 消炎（药
  • 抗VEGF

7. 眼科给药系统市场（依给药装置类型）

  • 隐形眼镜药物输送
  • 眼内植入
  • 微型针
  • 眼内植入物
  • 眼药水喷雾
  • 外用凝胶

8. 眼科给药系统市场（依产品类型）

  • 非处方药处方
  • 处方药
    • 控制释放製剂
    • 标准处方

9. 眼科给药系统市场（按剂型）

  • 液体製剂
  • 半固态製剂
    • 奶油
    • 凝胶
    • 软膏
  • 固态製剂
    • 胶囊
    • 药片

第 10 章眼科给药系统市场（依给药方式）

  • 眼
  • 玻璃体内
  • 眼周
  • 系统性
  • 话题

第11章眼科给药系统市场（依应用）

  • 过敏治疗
  • 干眼症
  • 青光眼
  • 眼部感染疾病
  • 视网膜疾病
  • 手术后恢復

第 12 章眼科给药系统市场（依最终使用者）

  • 医院
  • 眼科诊所
  • 研究组织

13. 美国眼科给药系统市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太地区眼科给药系统市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲眼科给药系统市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Alcon Vision LLC
  • Apotex Inc.
  • AptarGroup, Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Carl Zeiss AG
  • DifGen Pharmaceuticals LLC
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Gerresheimer AG
  • Iskon Remedies
  • Johnson & Johnson Service, Inc.
  • Mati Therapeutics, Inc.
  • Merck KGaA
  • MgShell SRL
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix Inc.
  • Oculis SA
  • Pfizer Inc.
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD51829D7

The Ophthalmic Drug Delivery System Market was valued at USD 15.50 billion in 2024 and is projected to grow to USD 16.84 billion in 2025, with a CAGR of 8.84%, reaching USD 25.79 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 15.50 billion
Estimated Year [2025] USD 16.84 billion
Forecast Year [2030] USD 25.79 billion
CAGR (%) 8.84%

The field of ophthalmic drug delivery has witnessed dynamic evolution over the past few years, driven by a continuous push towards enhanced patient outcomes and improved delivery mechanisms. In an era where precision and efficiency are paramount, the advent of advanced technologies is reshaping how medications are formulated and administered for ocular conditions. This transformation not only caters to the growing demands of patient-centric care but also bridges the gap between novel pharmacological research and clinical application. Innovations in micro- and nano-scale delivery systems have spurred significant progress in carrying out targeted therapies, minimizing systemic side effects, and extending therapeutic benefits. Researchers and healthcare professionals are increasingly focusing on formulation strategies that optimize bioavailability while preserving the stability and efficacy of drugs, making the field both challenging and rewarding. With improvements in diagnostic and imaging technologies, practitioners have more tools than ever before to tailor treatments to the unique needs of each patient. This seamless integration of various disciplines is laying the groundwork for a future where ocular therapies become more accessible, less invasive, and capable of addressing a broader range of conditions effectively.

As the industry steps into new territories of research, the intersection of science, technology, and clinical practice is setting new benchmarks. The ongoing dialogue between innovation and regulation further reinforces the commitment to achieving higher standards in safety and performance. This comprehensive overview lays the foundation for understanding the complexities and potential that exist within the ophthalmic drug delivery landscape.

Transformative Shifts Redefining Drug Delivery

The traditional landscape of ophthalmic drug delivery is undergoing a radical metamorphosis, marking a shift from conventional methods to disruptive innovations that enhance both efficiency and patient comfort. Emerging technologies are optimizing drug formulations and refining delivery mechanisms by integrating advanced materials and smart design principles. This transformative shift is characterized by the merging of interdisciplinary research with cutting-edge technology, which is paving the way for applications that were once considered unattainable. Rapid advancements in biotechnology have catalyzed the adoption of microfabrication techniques, enabling the design of precision drug delivery devices that target diseased ocular tissues with unprecedented accuracy.

This new paradigm is not just about technological prowess but also about redefining treatment protocols and patient management strategies. The integration of digital health solutions, such as telemedicine and wearable devices, is empowering practitioners to monitor treatment efficacy in real time and adjust dosages with remarkable precision. The convergence of innovation, clinical insights, and regulatory flexibility is enabling new therapeutic approaches that hold promise for improved safety profiles and enhanced patient adherence. As the industry moves forward, robust collaborations between academia, industry experts, and healthcare facilities are critical in ensuring that these groundbreaking technologies translate effectively from the lab to clinical environments, thus accelerating the overall pace of innovation in drug delivery systems.

Detailed Insights on Market Segmentation Strategies

The landscape of ophthalmic drug delivery is intricately divided into multiple segments that provide a comprehensive understanding of market dynamics and growth drivers. Evaluations based on drug type involve an in-depth analysis of formulations ranging from anti-allergy and anti-glaucoma agents to anti-infective, anti-inflammatory, and anti-VEGF molecules. Each category plays a critical role in addressing specific ocular challenges, thereby propelling market expansion. Delivery device type further broadens the focus, exploring technology across contact lens drug delivery systems, intraocular implants, microneedle systems, ocular inserts, ophthalmic sprays, and topical gels. This technical variety not only showcases the extent of innovation but also highlights efforts to reduce invasiveness and improve patient compliance.

Product type segmentation investigates both over-the-counter drug formulations and prescription drug formulations, where the latter is segmented further into controlled-release and standard formulations, offering tailored solutions through precise dosing methodologies. In addition, formulation type categorizes the market based on liquid, semi-solid, and solid formulations. The semi-solid category, which includes creams, gels, and ointments, and the solid formulations segment, emphasizing capsules and tablets, reveal how conventional therapies are evolving to meet modern therapeutic requirements. Moreover, the mode of delivery perspective examines intraocular, intravitreal, periocular, systemic, and topical approaches, while application-based segmentation covers an expansive range from allergy treatment and dry eye syndrome to glaucoma, ocular infections, retinal disorders, and surgical recovery. Finally, end user analysis focuses on the critical hubs such as hospitals, specialized ophthalmic clinics, and research organizations, each contributing unique insights to the overall growth story.

Based on Drug Type, market is studied across Anti-Allergy, Anti-Glaucoma, Anti-Infective, Anti-Inflammatory, and Anti-VEGF.

Based on Delivery Device Type, market is studied across Contact Lens Drug Delivery, Intraocular Implants, Microneedles, Ocular Inserts, Ophthalmic Sprays, and Topical Gels.

Based on Product Type, market is studied across Over-The-Counter Drug Formulations and Prescription Drug Formulations. The Prescription Drug Formulations is further studied across Controlled-Release Formulations and Standard Formulations.

Based on Formulation Type, market is studied across Liquid Formulations, Semi-Solid Formulations, and Solid Formulations. The Semi-Solid Formulations is further studied across Creams, Gels, and Ointments. The Solid Formulations is further studied across Capsules and Tablets.

Based on Mode Of Delivery, market is studied across Intraocular, Intravitreal, Periocular, Systemic, and Topical.

Based on Application, market is studied across Allergy Treatment, Dry Eye Syndrome, Glaucoma, Ocular Infections, Retinal Disorders, and Surgical Recovery.

Based on End User, market is studied across Hospitals, Ophthalmic Clinics, and Research Organizations.

Geographical Market Opportunities and Trends

Regional analysis provides a nuanced understanding of how market opportunities differ across key geographical areas. In the Americas, the evolving healthcare infrastructure paired with aggressive research initiatives is fostering rapid innovation and wide adoption of new drug delivery technologies. Simultaneously, the combined markets of Europe, the Middle East, and Africa face a multifaceted challenge, where a mix of regulatory stringencies and emerging markets juxtapose with established healthcare systems, prompting tailored strategies for different regions. Accelerated investments in research and development in these areas are setting the stage for groundbreaking therapies that converge global expertise and local market needs. In the Asia-Pacific, burgeoning economies and increasing healthcare awareness contribute significantly to market growth. The region is witnessing a surge in innovative startups and government initiatives designed to support high-tech advancements, making it a vital segment in the global framework of ophthalmic drug delivery systems. The collective insights drawn from these regions help in understanding market maturity, forecasting growth trajectories, and identifying potential collaboration hubs for accelerating industry progress.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Industry Players Shaping Market Dynamics

An analysis of key companies in the ophthalmic drug delivery space reveals a landscape marked by robust competition and continual innovation among several renowned organizations. Industry leaders including Abbott Laboratories and AbbVie Inc. are consistently pushing the envelope through research and development strategies that prioritize patient safety and technological excellence. Alcon Vision LLC and Apotex Inc. have distinguished themselves with their commitment to pioneering drug solutions that blend advanced delivery systems with innovative formulations. Companies like AptarGroup, Inc. and Bausch Health Companies Inc. continue to refine product designs and expand their portfolios to meet the evolving demands of ocular therapeutics.

Prominent players such as Bayer AG and Carl Zeiss AG have leveraged their extensive experience in medical technology to drive adoption and integration of state-of-the-art solutions in drug delivery. DifGen Pharmaceuticals LLC and EyePoint Pharmaceuticals, Inc. are further contributing to the diversification of the market through strategic innovations and targeted research initiatives. Leading multinational corporations including F. Hoffmann-La Roche AG, Genentech, Inc., and Gerresheimer AG continue to influence market trends significantly. Other key contributors such as Iskon Remedies, Johnson & Johnson Service, Inc., Mati Therapeutics, Inc., and Merck KGaA hold critical market positions with advanced formulations and impactful solutions. MgShell S.R.L., Nicox SA, and Novartis AG, alongside Ocular Therapeutix Inc., Oculis SA, Pfizer Inc., Recipharm AB, and Regeneron Pharmaceuticals, Inc., collectively shape market dynamics with their forward-thinking strategies. Additional significant players in the industry, Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Terumo Corporation, and Teva Pharmaceutical Industries Ltd. are also leading drivers of market evolution, continuously advocating improvements in ophthalmic drug delivery techniques.

The report delves into recent significant developments in the Ophthalmic Drug Delivery System Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alcon Vision LLC, Apotex Inc., AptarGroup, Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, DifGen Pharmaceuticals LLC, EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Gerresheimer AG, Iskon Remedies, Johnson & Johnson Service, Inc., Mati Therapeutics, Inc., Merck KGaA, MgShell S.R.L., Nicox SA, Novartis AG, Ocular Therapeutix Inc., Oculis SA, Pfizer Inc., Recipharm AB, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Terumo Corporation, and Teva Pharmaceutical Industries Ltd.. Strategic Recommendations for Market Leadership

Industrial stakeholders seeking to secure market leadership in ophthalmic drug delivery are encouraged to adopt a multi-faceted strategy built around innovation, collaboration, and adaptability. Investment in research and development remains pivotal, particularly in embracing technologies that facilitate precise drug targeting and controlled-release mechanisms. An emphasis on fostering collaborations with academic institutions and specialized research centers can yield novel insights and streamline the conversion of laboratory breakthroughs into clinically viable applications. Furthermore, pursuing regulatory clarity and establishing open channels with regulatory authorities can facilitate smoother approvals and foster investor confidence.

Stakeholders should also consider expanding their market reach by leveraging digital transformation tools. Integrating data analytics and real-time monitoring systems with traditional clinical practices can optimize dosage accuracy and improve patient outcomes. Building strong alliances across geographical regions will prove beneficial in understanding local nuances and tailoring products to meet specific regional demands. Additionally, investment in training and development programs for healthcare professionals ensures that advanced drug delivery systems are implemented safely and effectively. This dynamic approach not only positions companies as technology leaders but also enhances their reputation as innovators committed to patient-centric care. Ultimately, these strategic recommendations are designed to empower industry leaders to not only anticipate but also shape the future direction of ophthalmic drug delivery trends.

Conclusive Insights and Future Outlook

In summary, the evolving landscape of ophthalmic drug delivery is a testament to the relentless pursuit of innovation and excellence within the medical community. From the development of novel drug formulations to groundbreaking delivery systems, every aspect of this market is being reshaped by technological advancements and strategic foresight. Detailed segmentation analysis reveals a complex yet promising structure that covers diverse drug types, specialized delivery devices, and a range of formulations suited to address specific ocular conditions. Regional disparities further add layers of opportunity and challenge, stimulating customized strategies that resonate with local market dynamics.

The collective contributions of influential companies identified in this analysis underscore the competitive and innovative spirit driving the sector forward. Strategic partnerships, vigorous R&D investments, and the integration of digital health tools are paving the way for transformative changes in how ocular therapies are delivered and managed. As the field continues to evolve, it is clear that sustained emphasis on interdisciplinary collaboration, regulatory compliance, and market-specific tailoring will be integral to meeting both current and future demands. In essence, the path ahead is as challenging as it is promising, offering numerous opportunities for those positioned at the forefront of ophthalmic drug delivery innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population contributing to heightened need for advanced drug delivery systems
      • 5.1.1.2. Growing interest in biodegradable and biocompatible drug carriers for sustained release in eyes
      • 5.1.1.3. Supportive government initiatives and regulatory approvals encouraging adoption of novel ophthalmic drug delivery solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Supply chain disruptions and potential risk of product recalls
      • 5.1.2.2. Complexity of drug formulation and stability issues in ophthalmic drug delivery development
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnership & collaborations to develop advanced next-generation therapies
      • 5.1.3.2. Surging investments and funding to advance ocular drug delivery innovation
    • 5.1.4. Challenges
      • 5.1.4.1. Risks associated with side effects and safety in ophthalmic drug delivery
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising need for anti-glaucoma medications to prevent damage to the optic nerve
    • 5.2.2. Delivery Device Type: Growing significance of intraocular implants owing to their long-term controlled drug release
    • 5.2.3. Product Type: Increasing preference for over-the-counter drug formulations owing to their easy accessibility and widespread consumer trust
    • 5.2.4. Formulation Type: Growing utilization of semi-solid formulations for enhancing drug absorption and therapeutic efficacy
    • 5.2.5. Mode Of Delivery: Increasing adoption of intraocular delivery system owing to its precise targeting capability
    • 5.2.6. Application: Expanding applications of ophthalmic drug delivery systems for Glaucoma owing to its progressive nature
    • 5.2.7. End User: Rising significance of ophthalmic drug delivery system in ophthalmic clinics for providing specialized eye care and treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ophthalmic Drug Delivery System Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-Allergy
  • 6.3. Anti-Glaucoma
  • 6.4. Anti-Infective
  • 6.5. Anti-Inflammatory
  • 6.6. Anti-VEGF

7. Ophthalmic Drug Delivery System Market, by Delivery Device Type

  • 7.1. Introduction
  • 7.2. Contact Lens Drug Delivery
  • 7.3. Intraocular Implants
  • 7.4. Microneedles
  • 7.5. Ocular Inserts
  • 7.6. Ophthalmic Sprays
  • 7.7. Topical Gels

8. Ophthalmic Drug Delivery System Market, by Product Type

  • 8.1. Introduction
  • 8.2. Over-The-Counter Drug Formulations
  • 8.3. Prescription Drug Formulations
    • 8.3.1. Controlled-Release Formulations
    • 8.3.2. Standard Formulations

9. Ophthalmic Drug Delivery System Market, by Formulation Type

  • 9.1. Introduction
  • 9.2. Liquid Formulations
  • 9.3. Semi-Solid Formulations
    • 9.3.1. Creams
    • 9.3.2. Gels
    • 9.3.3. Ointments
  • 9.4. Solid Formulations
    • 9.4.1. Capsules
    • 9.4.2. Tablets

10. Ophthalmic Drug Delivery System Market, by Mode Of Delivery

  • 10.1. Introduction
  • 10.2. Intraocular
  • 10.3. Intravitreal
  • 10.4. Periocular
  • 10.5. Systemic
  • 10.6. Topical

11. Ophthalmic Drug Delivery System Market, by Application

  • 11.1. Introduction
  • 11.2. Allergy Treatment
  • 11.3. Dry Eye Syndrome
  • 11.4. Glaucoma
  • 11.5. Ocular Infections
  • 11.6. Retinal Disorders
  • 11.7. Surgical Recovery

12. Ophthalmic Drug Delivery System Market, by End User

  • 12.1. Introduction
  • 12.2. Hospitals
  • 12.3. Ophthalmic Clinics
  • 12.4. Research Organizations

13. Americas Ophthalmic Drug Delivery System Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Ophthalmic Drug Delivery System Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Ophthalmic Drug Delivery System Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. MERIT's strategic acquisition of OSOD enhances their preclinical to clinical ophthalmic drug delivery capabilities
    • 16.3.2. Merger of Tenpoint and Visus Therapeutics to pioneer advanced ophthalmic medicines
    • 16.3.3. MgShell raises over EUR 850,000 to transform ophthalmic drug delivery with magnesium-based innovation
    • 16.3.4. SpyGlass Pharma advances clinical trials for revolutionary drug delivery platform in glaucoma care
    • 16.3.5. Clearside Biomedical and Arctic Vision partner with Santen for ARVN001 commercialization in China
    • 16.3.6. Alcon unveils advanced drug delivery systems at AAO 2024, setting new benchmarks in ophthalmic care efficiency and precision
    • 16.3.7. Collaboration between Ripple Therapeutics and AbbVie aims to enhance glaucoma treatment with biodegradable sustained-release implants
    • 16.3.8. Visiox Pharmaceuticals announces merger with Ocuvex Therpeutics
    • 16.3.9. Genentech's reintroduction of Susvimo enhances ophthalmic treatment landscape for wet AMD patients
    • 16.3.10. DifGen's strategic acquisition enhances ophthalmic drug delivery capabilities and expands manufacturing footprint
    • 16.3.11. N4 Pharma accelerates commercialization of novel ophthalmic delivery systems targeting glaucoma market
    • 16.3.12. AffaMed's DEXTENZA gains regulatory momentum in Asia with Singapore HSA's NDA acceptance
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. Johnson & Johnson Service, Inc.
    • 16.4.2. AbbVie Inc.
    • 16.4.3. Carl Zeiss AG
    • 16.4.4. Alcon Vision LLC

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Alcon Vision LLC
  • 4. Apotex Inc.
  • 5. AptarGroup, Inc.
  • 6. Bausch Health Companies Inc.
  • 7. Bayer AG
  • 8. Carl Zeiss AG
  • 9. DifGen Pharmaceuticals LLC
  • 10. EyePoint Pharmaceuticals, Inc.
  • 11. F. Hoffmann-La Roche AG
  • 12. Genentech, Inc.
  • 13. Gerresheimer AG
  • 14. Iskon Remedies
  • 15. Johnson & Johnson Service, Inc.
  • 16. Mati Therapeutics, Inc.
  • 17. Merck KGaA
  • 18. MgShell S.R.L.
  • 19. Nicox SA
  • 20. Novartis AG
  • 21. Ocular Therapeutix Inc.
  • 22. Oculis SA
  • 23. Pfizer Inc.
  • 24. Recipharm AB
  • 25. Regeneron Pharmaceuticals, Inc.
  • 26. Santen Pharmaceutical Co., Ltd.
  • 27. Sun Pharmaceutical Industries, Inc.
  • 28. Terumo Corporation
  • 29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET MULTI-CURRENCY
  • FIGURE 2. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET MULTI-LANGUAGE
  • FIGURE 3. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET RESEARCH PROCESS
  • FIGURE 4. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET DYNAMICS
  • TABLE 7. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. EGYPT OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. FINLAND OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLIO